Market PotentialA notable 7 in 10 smokers want to quit, indicating a strong market demand for effective cessation aids.
Product DevelopmentThe company has successfully collected long-term safety data for cytisinicline, fulfilling a key NDA submission requirement for smoking cessation.
Regulatory ProgressThe planned Phase 3 ORCA-V2 vaping cessation study has received FDA alignment, paving the way for future supplemental NDA submission for vaping cessation.